Cenduit to Launch Quantum Interactive™ Solution at DIA 2017
Cenduit LLC, a joint venture between QuintilesIMS and Thermo Fisher Scientific, is showcasing its solutions as an interactive response technology (IRT) specialist at DIA next week, June 19-21, in Chicago. Same Osman, Cenduit's new CEO, will present at the show, and the company will launch its newest study build software, Quantum Interactive™.
Quantum Interactive is technology-based and increases IRT quality by creating a functioning prototype of an initial study build within minutes, according to the company. It is a user-friendly interface that guides the study building process for faster requirements discovery and is highly configurable, regardless of study design.
Read the full release here.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Full Phase IIIb BATURA Trial Results Show Airsupra Cuts Severe Exacerbations by 47% in Mild Asthma
May 20th 2025Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol monotherapy in reducing severe asthma exacerbations and systemic corticosteroid exposure, reinforcing its role as a next-generation, anti-inflammatory rescue therapy for mild asthma patients.
